Jackson Square Capital LLC Has $2.50 Million Stock Holdings in Danaher Co. (NYSE:DHR)

Jackson Square Capital LLC trimmed its stake in Danaher Co. (NYSE:DHR - Free Report) by 8.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,868 shares of the conglomerate's stock after selling 1,052 shares during the period. Jackson Square Capital LLC's holdings in Danaher were worth $2,495,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Decker Retirement Planning Inc. bought a new stake in shares of Danaher in the 4th quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America acquired a new position in Danaher during the third quarter worth $39,000. MidAtlantic Capital Management Inc. bought a new stake in Danaher during the 3rd quarter worth about $40,000. FSA Wealth Management LLC acquired a new stake in Danaher in the 3rd quarter valued at about $50,000. Finally, Darwin Wealth Management LLC acquired a new position in shares of Danaher during the third quarter worth approximately $55,000. Institutional investors own 79.05% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on DHR. Scotiabank initiated coverage on shares of Danaher in a research report on Monday, December 23rd. They issued a "sector perform" rating and a $265.00 price objective for the company. Royal Bank of Canada cut their price target on Danaher from $333.00 to $311.00 and set an "outperform" rating on the stock in a research note on Wednesday, October 23rd. Bank of America upgraded Danaher from a "neutral" rating to a "buy" rating and set a $290.00 price objective for the company in a research report on Friday, December 13th. Evercore ISI upped their target price on shares of Danaher from $275.00 to $278.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st. Finally, UBS Group lowered their target price on shares of Danaher from $309.00 to $305.00 and set a "buy" rating for the company in a report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, Danaher presently has an average rating of "Moderate Buy" and an average target price of $286.80.

Danaher Stock Down 1.4 %

DHR stock traded down $3.49 during trading hours on Friday, reaching $238.41. 3,044,734 shares of the stock were exchanged, compared to its average volume of 2,640,177. The company has a market cap of $172.20 billion, a price-to-earnings ratio of 45.50, a PEG ratio of 4.23 and a beta of 0.83. The firm's 50-day moving average is $234.85 and its 200-day moving average is $253.42. Danaher Co. has a 12 month low of $222.53 and a 12 month high of $281.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts' consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business's revenue was up 3.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.02 EPS. On average, equities research analysts expect that Danaher Co. will post 7.49 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. The ex-dividend date of this dividend is Friday, December 27th. Danaher's payout ratio is 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.